Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jun;40(6):1360–1365. doi: 10.1128/aac.40.6.1360

Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii.

J M Jacobson 1, M Davidian 1, P M Rainey 1, R Hafner 1, R H Raasch 1, B J Luft 1
PMCID: PMC163331  PMID: 8726001

Abstract

Pyrimethamine pharmacokinetics were studied in 11 human immunodeficiency virus (HIV)-positive patients who were seropositive for exposure to Toxoplasma gondii and were taking zidovudine (AIDS Clinical Trials Group Protocol 102). Pyrimethamine was administered at 50 mg daily for 3 weeks to achieve steady state, and pharmacokinetic profiles were determined after administration of the last dose. Noncompartmental and compartmental analyses were performed. Population pharmacokinetic analysis assuming a one-compartment model yielded the following estimates: area under the 24-h concentration-time curve, 42.7 +/- 12.3 micrograms.h/ml; halflife, 139 +/- 34 h; clearance, 1.28 +/- 0.41 liters/h; volume of distribution, 246 +/- 641; and absorption rate constant, 1.5 +/- 1.3 liters/h. These values are similar to those seen in subjects without HIV infection. Pyrimethamine pharmacokinetics did not differ significantly in those subjects who were intravenous drug users. Adverse effects were noted in 73% of those initially enrolled in this study, leading to discontinuation for 38%. No association was noted between pyrimethamine levels and the incidence of adverse events. No significant differences were seen in zidovudine pharmacokinetic parameters obtained from studies performed before and during treatment with pyrimethamine. In summary, pyrimethamine exhibited pharmacokinetics in HIV-infected patients that were similar to those in non-HIV-infected subjects and it did not alter the pharmacokinetics of zidovudine in these patients.

Full Text

The Full Text of this article is available as a PDF (268.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dannemann B., McCutchan J. A., Israelski D., Antoniskis D., Leport C., Luft B., Nussbaum J., Clumeck N., Morlat P., Chiu J. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med. 1992 Jan 1;116(1):33–43. doi: 10.7326/0003-4819-116-1-33. [DOI] [PubMed] [Google Scholar]
  2. Grant I. H., Gold J. W., Rosenblum M., Niedzwiecki D., Armstrong D. Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS. 1990 Jun;4(6):519–521. [PubMed] [Google Scholar]
  3. Haverkos H. W. Assessment of therapy for toxoplasma encephalitis. The TE Study Group. Am J Med. 1987 May;82(5):907–914. doi: 10.1016/0002-9343(87)90151-3. [DOI] [PubMed] [Google Scholar]
  4. KAUFMAN H. E., CALDWELL L. A. Pharmacological studies of pyrimethamine (daraprim) in man. AMA Arch Ophthalmol. 1959 Jun;61(6):885–890. doi: 10.1001/archopht.1959.00940090887003. [DOI] [PubMed] [Google Scholar]
  5. Leport C., Meulemans A., Robine D., Dameron G., Vildé J. L. Levels of pyrimethamine in serum and penetration into brain tissue in humans. AIDS. 1992 Sep;6(9):1040–1041. doi: 10.1097/00002030-199209000-00021. [DOI] [PubMed] [Google Scholar]
  6. Leport C., Raffi F., Matheron S., Katlama C., Regnier B., Saimot A. G., Marche C., Vedrenne C., Vilde J. L. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. Am J Med. 1988 Jan;84(1):94–100. doi: 10.1016/0002-9343(88)90014-9. [DOI] [PubMed] [Google Scholar]
  7. Levy R. M., Bredesen D. E., Rosenblum M. L. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg. 1985 Apr;62(4):475–495. doi: 10.3171/jns.1985.62.4.0475. [DOI] [PubMed] [Google Scholar]
  8. Luft B. J., Hafner R., Korzun A. H., Leport C., Antoniskis D., Bosler E. M., Bourland D. D., 3rd, Uttamchandani R., Fuhrer J., Jacobson J. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med. 1993 Sep 30;329(14):995–1000. doi: 10.1056/NEJM199309303291403. [DOI] [PubMed] [Google Scholar]
  9. Luft B. J., Remington J. S. AIDS commentary. Toxoplasmic encephalitis. J Infect Dis. 1988 Jan;157(1):1–6. doi: 10.1093/infdis/157.1.1. [DOI] [PubMed] [Google Scholar]
  10. Mansor S. M., Navaratnam V., Mohamad M., Hussein S., Kumar A., Jamaludin A., Wernsdorfer W. H. Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. Br J Clin Pharmacol. 1989 Mar;27(3):381–386. doi: 10.1111/j.1365-2125.1989.tb05381.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Opravil M., Keusch G., Lüthy R. Pyrimethamine inhibits renal secretion of creatinine. Antimicrob Agents Chemother. 1993 May;37(5):1056–1060. doi: 10.1128/aac.37.5.1056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Roberts W. L., Reynolds K. M., Heimer R., Jatlow P. I., Rainey P. M. Pyrimethamine analysis by enzyme inhibition and HPLC assays. Am J Clin Pathol. 1995 Jul;104(1):82–88. doi: 10.1093/ajcp/104.1.82. [DOI] [PubMed] [Google Scholar]
  13. Ruf B., Schürmann D., Bergmann F., Schüler-Maué W., Grünewald T., Gottschalk H. J., Witt H., Pohle H. D. Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1993 May;12(5):325–329. doi: 10.1007/BF01964427. [DOI] [PubMed] [Google Scholar]
  14. Sheiner L. B., Ludden T. M. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol. 1992;32:185–209. doi: 10.1146/annurev.pa.32.040192.001153. [DOI] [PubMed] [Google Scholar]
  15. Steimer J. L., Mallet A., Golmard J. L., Boisvieux J. F. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev. 1984;15(1-2):265–292. doi: 10.3109/03602538409015066. [DOI] [PubMed] [Google Scholar]
  16. Weidekamm E., Plozza-Nottebrock H., Forgo I., Dubach U. C. Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting. Bull World Health Organ. 1982;60(1):115–122. [PMC free article] [PubMed] [Google Scholar]
  17. Weiss L. M., Harris C., Berger M., Tanowitz H. B., Wittner M. Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS. J Infect Dis. 1988 Mar;157(3):580–583. doi: 10.1093/infdis/157.3.580. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES